Vigil Neuroscience Stock Forum

$Vigil Neuroscience (VIGL.US)$ Vigil Neuroscience | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Vida Ventures GP III, L.L.C.(12.7%),Stefan Vitorovic(12.7%), etc.
SEC· 21 mins ago

$Vigil Neuroscience (VIGL.US)$ JMP Buy Rating Target $23

$Vigil Neuroscience (VIGL.US)$
Vigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927
Vigil Neuroscience (Nasdaq: VIGL) announced that the FDA has removed the partial clinical hold on its Phase 1 trial of VG-3927, a potential treatment for Alzheimer's disease. The decision was based on non-clinical and clinical data from the ongoing trial. Interim data from July 2024 showed a favorable safety and tolerability profile, predictable pharmacokinetics supporting once-daily ...

$Vigil Neuroscience (VIGL.US)$
Vigil Neuroscience Announces Interim Data from its Ongoing Phase 1 Clinical Trial Evaluating VG-3927 in Healthy Volunteers Supporting Continued Development in Alzheimer’s Disease
Vigil Neuroscience (Nasdaq: VIGL) has announced promising interim data from its ongoing Phase 1 clinical trial of VG-3927, a potential once-daily oral therapy for Alzheimer's disease (AD).
The trial, which has enrolled 80 healthy volunteers, demonstrated a favorable safety and tolerabi...

$Vigil Neuroscience (VIGL.US)$
Vigil Announces Upcoming Presentations on its Small Molecule TREM2 Agonist VG-3927 at the 2024 Alzheimer's Association International Conference
-July 30 9AM EDT
Vigil Neuroscience (Nasdaq: VIGL) announced three presentations on its small molecule TREM2 agonist VG-3927at the 2024 Alzheimer's Association International Conference (AAIC) in Philadelphia. The presentations include:
1. An oral presentation on the characterization of VG-3927 for clinical development in...

$Vigil Neuroscience (VIGL.US)$
Vigil Neuroscience Provides Update on Clinical Development Strategy to Pursue Potential Accelerated Approval Pathway for Iluzanebart in ALSP
Vigil Neuroscience (Nasdaq: VIGL) has updated its clinical development strategy for iluzanebart in adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP)following a Type C Meeting with the FDA.
The company will preserve the IGNITE dataset for a final analysis at 12 months, foregoing an interim anal...

$Vigil Neuroscience (VIGL.US)$
But it barely hit even 10 dollars. why is it so? hmm